Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 2
This study is comparing olaparib on its own and in combination with AZD6738 for triple negative breast cancer that has spread.
To take part in the study, the team want to know if your cancer has changes () in the of the HRR (Human Recombination Repair) proteins. For this test, they use a piece of tissue that was taken when you were first diagnosed with breast cancer. Or a piece of tissue that was collected later from a part of the body to which the cancer had spread.
This study was also looking at AZD1775 in combination with olaparib. But this combination is no longer been used.
Recruitment start: 28 November 2017
Recruitment end: 9 November 2020
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Andrew Tutt
AstraZeneca
PAREXEL
Last reviewed: 25 Mar 2021
CRUK internal database number: 15540
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
